Skip to main content
. Author manuscript; available in PMC: 2022 May 15.
Published in final edited form as: Clin Cancer Res. 2021 Sep 13;27(22):6235–6249. doi: 10.1158/1078-0432.CCR-21-0971

Figure 3.

Figure 3

(A) Flow Cytometric analysis of CD103+ DC populations in MOC2 and LY2 tumors. MOC2 tumors were taken 3 days after RT, NK cell depletion, and FLT3L therapy. LY2 tumors were taken 9 days post RT, anti-CD25, and FLT3L HDT; *p≤0.1 **p≤0.05 n=6. (B) Flow Cytometric analysis of CD8 T cell populations in MOC2 tumors 24 days after RT and 10 days after the start of FLT3L therapy; *p≤0.1, **p≤0.05; n=5. (C) Schematic of experimental procedure for CD4 and CD8 T cell depletion in C57BL/6 mice bearing MOC2 tumors depicts days of administration of 8 Gy RT (red lightning bolt), beginning of antibody therapy (blue arrow), and FLT3L HDT therapy (green arrow). (D) MOC2 Tumor volumes of C57BL/6 and RAG−/− mice treated with RT, anti-CD25, anti-CD137, and depleted of NK cells (black line), treated with FLT3L HDT therapy (green line) and depleted of CD4 T cells (blue line), CD8 T cells (red line), and RAG−/− mice devoid of CD4 and CD8 T cells (pink line); n=7. (E) FLT3L and IL-15 levels in serum of T cell-depleted (ELISA); n=6. (F) Schematic of experimental procedure involving WT C57BL/6 and BATF3−/− mice to be treated with RT, anti-CD25, anti-CD137, depleted of NK cells, and FLT3L HDT therapy depicts days of RT (red lightning bolt), beginning of antibody therapy (blue arrow), and FLT3L HDT therapy (green arrow). (G) MOC2 tumor volumes of WT C57BL/6 mice treated with RT, anti-CD25, and anti-CD137 (black line), NK cell depletion and FLT3L HDT therapy (green line), and BATF3−/− mice treated with RT, anti-CD25, anti-CD137, NK cell depletion, and FLT3L HDT therapy (blue line); n=7. (H) FLT3L serum levels (ELISA) in WT C57BL/6 mice and BATF3−/− mice treated with RT, anti-CD25, anti-CD137, NK cell depletion, and FLT3L HDT therapy; N=5. (I) Flow cytometric analysis of CD4 and CD8 T cell populations in tumors of WT C57BL/6 mice and BATF3−/− mice treated with RT, anti-CD137, anti-CD25, NK cell depletion, and FLT3L HDT therapy; n=5.